Assessment of the test characteristics of an instant anti-CCP2 test compared to the anti-CCP2 elisa in serum

Published: 24-08-2006 Last updated: 20-05-2024

-What are the testcharacteristics of an anti-CCP2 quicktest (sensitivity, specificity, positive and negative predictive value, kappa statististics) using capillary or venous blood compared to the golden standard, the anti-CCP2 Elisa in serum?-What...

Ethical review Approved WMO

Status Pending

Health condition type Synovial and bursal disorders

Study type Observational invasive

Summary

ID

NL-OMON30010

Source

ToetsingOnline

Brief title

Test characteristics of an instant anti-CCP2 test

Condition

Synovial and bursal disorders

Synonym

arthritis, Reumatoid Arthritis

Research involving

Human

Sponsors and support

Primary sponsor: Sint Maartenskliniek

Source(s) of monetary or material Support: Ministerie van OC&W, Eurodiagnostics,

Arnhem

1 - Assessment of the test characteristics of an instant anti-CCP2 test compared to ... 26-05-2025

Intervention

Keyword: anti-CCP, diagnostic, early arthritis

Outcome measures

Primary outcome

Results from the anti-CCP2 quicktest with capillary and venous blood are compared to each other and to the anti-CCP2 elisa in serum using dichotomeous and trichotomeous distributions (negatief, weakly positive and positive (3*3 table) or positive and negative (2*2) table). Testcharacteristics are decribed using sensitivity, specificity, positive and negative predictive value.

Secondary outcome

Pragmatic aspects including needed time, feasability and the percentage of failed tests are described qualitatively and quantitatively.

Study description

Background summary

Recently a new diagnostic test for Rheumatoid Arthritis has been developed - the anti-CCP2 test - which is as sensitive (60%) but more specific for RA (95%) compared to rheumatoid factor. The additional value of anti-CCP2 has been established in prospective studies.

The presence of anti-CCP antibodies is measured using an Elisa, which takes a few days. If a quicktest for anti-CCP2 was available, this could decrease delay of diagnosis and treatment. Recently a 5 minute anti-CCP2 test has been developed that can be used on capillary or venous blood.

Study objective

- -What are the testcharacteristics of an anti-CCP2 quicktest (sensitivity, specificity, positive and negative predictive value, kappa statististics) using capillary or venous blood compared to the golden standard, the anti-CCP2 Elisa in serum?
- -What are pragmatic aspects of this test, including average needed time,
 - 2 Assessment of the test characteristics of an instant anti-CCP2 test compared to ... 26-05-2025

percentage number of failed tests, feasability.

Study design

Two anti-CCP2 quicktests will be done on RA patients at their home or at the outpatient clinic. Both venous blood and capillary blood will be drawn. Results for each test are noted as well as pragmatic aspect and baseline, medication and RA related data.

Study burden and risks

The Burdon for the patient include sampling of venous blood and capillary blood ("finger prick") and providing some baseline data. Time required is once 10 minutes and there are no associated risks bu a bruise from the venous blood sampling. The anti-CCP2 status is already known for all patients, so they do not receive new disease information.

Contacts

Public

Sint Maartenskliniek

Hengstdal 3 6522JV Nederland

Scientific

Sint Maartenskliniek

Hengstdal 3 6522JV Nederland

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

Rheumatoid arthritis informed consent given Aerea of Nijmegen Previous Anti-CCP2 status determined

Exclusion criteria

none

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-09-2006

Enrollment: 160

Type: Anticipated

Ethics review

Approved WMO

Application type: First submission

Review commission: CMO regio Arnhem-Nijmegen (Nijmegen)

4 - Assessment of the test characteristics of an instant anti-CCP2 test compared to ... 26-05-2025

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL13564.091.06